- Home
- CAVA vs BBIO Comparison
CAVA vs BBIO Comparison
Compare CAVA & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAVA
- BBIO
- Stock Information
- Founded
- CAVA 2006
- BBIO 2015
- Country
- CAVA United States
- BBIO United States
- Employees
- CAVA N/A
- BBIO N/A
- Industry
- CAVA Restaurants
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- CAVA Consumer Discretionary
- BBIO Health Care
- Exchange
- CAVA Nasdaq
- BBIO Nasdaq
- Market Cap
- CAVA 9.0B
- BBIO 7.6B
- IPO Year
- CAVA 2023
- BBIO 2019
- Fundamental
- Price
- CAVA $74.62
- BBIO $41.73
- Analyst Decision
- CAVA Buy
- BBIO Strong Buy
- Analyst Count
- CAVA 14
- BBIO 13
- Target Price
- CAVA $118.07
- BBIO $56.67
- AVG Volume (30 Days)
- CAVA 3.5M
- BBIO 2.5M
- Earning Date
- CAVA 05-15-2025
- BBIO 07-31-2025
- Dividend Yield
- CAVA N/A
- BBIO N/A
- EPS Growth
- CAVA 274.67
- BBIO N/A
- EPS
- CAVA 1.20
- BBIO N/A
- Revenue
- CAVA $1,036,533,000.00
- BBIO $127,415,000.00
- Revenue This Year
- CAVA $26.28
- BBIO $102.05
- Revenue Next Year
- CAVA $21.53
- BBIO $54.69
- P/E Ratio
- CAVA $62.12
- BBIO N/A
- Revenue Growth
- CAVA 32.11
- BBIO N/A
- 52 Week Low
- CAVA $70.00
- BBIO $21.62
- 52 Week High
- CAVA $172.43
- BBIO $41.90
- Technical
- Relative Strength Index (RSI)
- CAVA 30.45
- BBIO 69.82
- Support Level
- CAVA $72.36
- BBIO $39.65
- Resistance Level
- CAVA $77.40
- BBIO $41.36
- Average True Range (ATR)
- CAVA 2.85
- BBIO 1.51
- MACD
- CAVA -0.25
- BBIO 0.35
- Stochastic Oscillator
- CAVA 20.16
- BBIO 97.37
About CAVA CAVA Group Inc.
Cava Group Inc owns and operates a chain of restaurants. It is the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. The company's dips, spreads, and dressings are centrally produced and sold in grocery stores. The company's operations are conducted as two reportable segments: CAVA and Zoes Kitchen. The company generates all of its revenue from the CAVA segment.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.